NCT00001249View on ClinicalTrials.gov

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 1989

Study Completion Date

October 31, 2000

Conditions

Leukemia, T-CellLymphoma, T-Cell, Cutaneous

Interventions

DRUG

Yttrium-90 radiolabeled anti-Tac antibody

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH